Terumo BCT receives grant to develop pathogen reduction technology

Terumo BCT handles blood component, therapeutic apheresis, and cellular technologies.
Terumo BCT handles blood component, therapeutic apheresis, and cellular technologies. | File photo

The Department of Defense has awarded Terumo BCT a three-year grant to further develop its Mirasol Pathogen Reduction Technology System

The grant is another collaboration between Terumo BCT and the U.S. government­­ to improve global blood safety This specific grant seeks to improve blood safety in transfusions for military personnel.

Terumo BCT handles blood component, therapeutic apheresis, and cellular technologies. Mirasol uses vitamin B2 and ultraviolet light to reduce viruses, bacteria and parasites, eliminating diseases such as Hepatitis C. The technology is available in over 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America.

Terumo BCT will use the award from the Peer Reviewed Medical Research Program, which is a component of the Department of Defense's Congressionally Directed Medical Research Programs. The grant could help develop the next-generation of Mirasol, which could lead to a reduction of pathogens in whole blood before being separated into components.

Contact Terumo BCT at 303-542-5396 or press@terumobct.com for more information.

Organizations in this Story

Terumo Bct, Inc.

Get notified the next time we write about Terumo Bct, Inc.!




Top